Clinical Cancer Research CR Balducci Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, J. J.
Right arrow Articles by Lippman, Scott. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J. J.
Right arrow Articles by Lippman, Scott. M.
Clinical Cancer Research Vol. 6, 1702-1710, May 2000
© 2000 American Association for Cancer Research

Clinical Trials

Predicting Cancer Development in Oral Leukoplakia: Ten Years of Translational Research1

J. Jack Lee2, Waun Ki Hong, Walter N. Hittelman, Li Mao, Reuben Lotan, Dong M. Shin, Steven E. Benner, Xiao-Chun Xu, Jin S. Lee, Vali M. Papadimitrakopoulou, Clarissa Geyer, Cherie Perez, Jack W. Martin, Adel K. El-Naggar and Scott. M. Lippman

Departments of Biostatistics [J. J. L.], Clinical Cancer Prevention [S. M. L., X. C. X., C. P.], Thoracic/Head and Neck Medical Oncology [W. K. H., L. M., R. L., D. M. S., J. S. L., V. M. P., C. G.], Head and Neck Surgery [J. W. M.], Clinical Investigation [W. N. H.], and Pathology [A. K. E.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Bristol-Myer Squibb, Wallingford, Connecticut 06492 [S. E. B.]

Our 10-year translational study of the oral premalignant lesion (OPL) model has advanced the basic understanding of carcinogenesis. Although retinoids have established activity in this model, a substantial percentage of our OPL patients progress to cancer, especially after treatment is stopped. On the basis of our 10-year OPL study, we have developed the first comprehensive tool for assessing cancer risk of OPL patients. This cancer risk assessment tool incorporates medical/demographic variables, epidemiological factors, and cellular and molecular biomarkers.

Between 1988 and 1991, 70 advanced OPL patients were enrolled in a chemoprevention trial of induction with high dose isotretinoin (1.5 mg/kg/day for 3 months) followed by 9 months of maintenance treatment with either low dose isotretinoin (0.5 mg/kg/day) or ß-carotene (30 mg/d; total treatment duration, 1 year). We assessed the relationship between cancer risk factors and time to cancer development by means of exploratory data analysis, logrank test, Cox proportional hazard model, and recursive partitioning.

With a median follow-up of 7 years, 22 of our 70 patients (31.4%) developed cancers in the upper aerodigestive tract following treatment. The overall cancer incidence was 5.7% per year. The most predictive factors of cancer risk are OPL histology, cancer history, and three of the five biomarkers we assessed (chromosomal polysomy, p53 protein expression, and loss of heterozygosity at chromosome 3p or 9p). In the multivariable Cox model, histology (P = 0.0003) and the combined biomarker score of chromosomal polysomy, p53, and loss of heterozygosity (P = 0.0008) are the strongest predictors for cancer development. Retinoic acid receptor ß and micronuclei were not associated with increased cancer risk.

We have demonstrated a successful strategy of comprehensive cancer risk assessment in OPL patients. Combining conventional medical/demographic variables and a panel of three biomarkers can identify high risk patients in our sample. This result will need to be validated by future studies. With the identification of high risk individuals, more efficient chemoprevention trials and molecular targeting studies can be designed.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. M. Lippman and E. T. Hawk
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Cancer Res., July 1, 2009; 69(13): 5269 - 5284.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
S. M. Lippman
Cancer Prevention Research: Back to the Future
Cancer Prevention Research, June 1, 2009; 2(6): 503 - 513.
[Full Text] [PDF]

Home page
 Brief Funct Genomic ProteomicHome page
N. S. Nagaraj
Evolving 'omics' technologies for diagnostics of head and neck cancer
Brief Funct Genomic Proteomic, March 9, 2009; (2009) elp004v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. A. Papadimitrakopoulou, J. J. Lee, W. N. William Jr, J. W. Martin, M. Thomas, E. S. Kim, F. R. Khuri, D. M. Shin, L. Feng, W. K. Hong, et al.
Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy
J. Clin. Oncol., February 1, 2009; 27(4): 599 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
X. Li, P. C. Galipeau, C. A. Sanchez, P. L. Blount, C. C. Maley, J. Arnaudo, D. A. Peiffer, D. Pokholok, K. L. Gunderson, and B. J. Reid
Single Nucleotide Polymorphism-Based Genome-Wide Chromosome Copy Change, Loss of Heterozygosity, and Aneuploidy in Barrett's Esophagus Neoplastic Progression
Cancer Prevention Research, November 1, 2008; 1(6): 413 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
E. Szabo
Assessing Efficacy in Early-Phase Cancer Prevention Trials: The Case of Oral Premalignancy
Cancer Prevention Research, October 1, 2008; 1(5): 312 - 315.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
B. J. Reid
Cancer Risk Assessment and Cancer Prevention: Promises and Challenges
Cancer Prevention Research, September 1, 2008; 1(4): 229 - 232.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. L. Hall, R. J. Shaw, E. A. Field, S. N. Rogers, D. N. Sutton, J. A. Woolgar, D. Lowe, T. Liloglou, J. K. Field, and J. M. Risk
p16 Promoter Methylation Is a Potential Predictor of Malignant Transformation in Oral Epithelial Dysplasia
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2174 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Lippman and J. V. Heymach
The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention
Clin. Cancer Res., July 15, 2007; 13(14): 4035 - 4041.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
D. Kademani
Oral Cancer
Mayo Clin. Proc., July 1, 2007; 82(7): 878 - 887.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. G. Izzo, T.-T. Wu, X. Wu, J. Ensor, R. Luthra, J. Pan, A. Correa, S. G. Swisher, C. K.S. Chao, W. N. Hittelman, et al.
Cyclin D1 Guanine/Adenine 870 Polymorphism With Altered Protein Expression Is Associated With Genomic Instability and Aggressive Clinical Biology of Esophageal Adenocarcinoma
J. Clin. Oncol., February 20, 2007; 25(6): 698 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. F. Poh, L. Zhang, D. W. Anderson, J. S. Durham, P. M. Williams, R. W. Priddy, K. W. Berean, S. Ng, O. L. Tseng, C. MacAulay, et al.
Fluorescence Visualization Detection of Field Alterations in Tumor Margins of Oral Cancer Patients.
Clin. Cancer Res., November 15, 2006; 12(22): 6716 - 6722.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Huang, M. R. Spitz, J. Gu, J.J. Lee, J. Lin, S. M.Lippman, and X. Wu
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions
Carcinogenesis, October 1, 2006; 27(10): 2034 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Lippman, J. J. Lee, J. W. Martin, A. K. El-Naggar, X. Xu, D. M. Shin, M. Thomas, L. Mao, H. A. Fritsche Jr., X. Zhou, et al.
Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia.
Clin. Cancer Res., May 15, 2006; 12(10): 3109 - 3114.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Perez-Ordonez, M Beauchemin, and R C K Jordan
Molecular biology of squamous cell carcinoma of the head and neck.
J. Clin. Pathol., May 1, 2006; 59(5): 445 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Lippman and J. J. Lee
Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Cancer Res., March 15, 2006; 66(6): 2893 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid
Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, M. Williams, C. F. Poh, D. Laronde, J. B. Epstein, S. Durham, H. Nakamura, K. Berean, A. Hovan, N. D. Le, et al.
Toluidine Blue Staining Identifies High-Risk Primary Oral Premalignant Lesions with Poor Outcome
Cancer Res., September 1, 2005; 65(17): 8017 - 8021.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. J.M. Braakhuis, R. H. Brakenhoff, and C. R. Leemans
Second Field Tumors: A New Opportunity for Cancer Prevention?
Oncologist, August 1, 2005; 10(7): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. S. Kim and W. K. Hong
An Apple a Day...Does It Really Keep the Doctor Away? The Current State of Cancer Chemoprevention
J Natl Cancer Inst, April 6, 2005; 97(7): 468 - 470.
[Full Text] [PDF]

Home page
 JCOHome page
S. M. Lippman, J. Sudbo, and W. K. Hong
Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development
J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Li, M. A. R. St. John, X. Zhou, Y. Kim, U. Sinha, R. C. K. Jordan, D. Eisele, E. Abemayor, D. Elashoff, N.-H. Park, et al.
Salivary Transcriptome Diagnostics for Oral Cancer Detection
Clin. Cancer Res., December 15, 2004; 10(24): 8442 - 8450.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Stearns, A. Coop, B. Singh, A. Gallagher, H. Yamauchi, R. Lieberman, M. Pennanen, B. Trock, D. F. Hayes, and M. J. Ellis
A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia
Clin. Cancer Res., November 15, 2004; 10(22): 7583 - 7591.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
J. Sudbo
Novel Management of Oral Cancer: A Paradigm of Predictive Oncology
Clin. Med. Res., November 1, 2004; 2(4): 233 - 242.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
U. Nair, H. Bartsch, and J. Nair
Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms
Mutagenesis, July 1, 2004; 19(4): 251 - 262.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
A. S. Tsao, E. S. Kim, and W. K. Hong
Chemoprevention of Cancer
CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Sudbo, S. M. Lippman, J. J. Lee, L. Mao, W. Kildal, A. Sudbo, S. Sagen, M. Bryne, A. El-Naggar, B. Risberg, et al.
The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia
N. Engl. J. Med., April 1, 2004; 350(14): 1405 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. O. Boyle
Cyclooxygenase Inhibition as a Target for Prevention of Tobacco-Related Cancers
Clin. Cancer Res., March 1, 2004; 10(5): 1557 - 1558.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goodin and S. J. Shiff
NSAIDs for the Chemoprevention of Oral Cancer: Promise or Pessimism?: Commentary re J. L. Mulshine et al., Randomized, Double-Blind, Placebo-Controlled, Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004.
Clin. Cancer Res., March 1, 2004; 10(5): 1561 - 1564.
[Full Text] [PDF]

Home page
 JCOHome page
I. Ganly and B. Singh
Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus?
J. Clin. Oncol., December 15, 2003; 21(24): 4476 - 4478.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman
Frontiers in Cancer Prevention Research
Cancer Res., September 15, 2003; 63(18): 5649 - 5655.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Lango, A. L. Wentzel, J. I. Song, S. Xi, D. E. Johnson, W. W. Lamph, L. Miller, and J. R. Grandis
Responsiveness to the Retinoic Acid Receptor-selective Retinoid LGD1550 Correlates with Abrogation of Transforming Growth Factor {alpha}/Epidermal Growth Factor Receptor Autocrine Signaling in Head and Neck Squamous Carcinoma Cells
Clin. Cancer Res., September 15, 2003; 9(11): 4205 - 4213.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Natarajan, M. Saeb, C. P. Crum, S. B. Woo, P. H. McKee, and J. G. Rheinwald
Co-Expression of p16INK4A and Laminin 5 {gamma}2 by Microinvasive and Superficial Squamous Cell Carcinomas in Vivo and by Migrating Wound and Senescent Keratinocytes in Culture
Am. J. Pathol., August 1, 2003; 163(2): 477 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. B. Armstrong, T. H. Taylor, and F. L. Meyskens Jr.
Point: Surrogate End Point Biomarkers Are Likely To Be Limited in Their Usefulness in the Development of Cancer Chemoprevention Agents against Sporadic Cancers
Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 589 - 592.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. G. Izzo, V. A. Papadimitrakopoulou, D. D. Liu, P. L. C. den Hollander, I. M. Babenko, J. Keck, A. K. El-Naggar, D. M. Shin, J. J. Lee, W. K. Hong, et al.
Cyclin D1 Genotype, Response to Biochemoprevention, and Progression Rate to Upper Aerodigestive Tract Cancer
J Natl Cancer Inst, February 5, 2003; 95(3): 198 - 205.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
J. Reibel
PROGNOSIS OF ORAL PRE-MALIGNANT LESIONS: SIGNIFICANCE OF CLINICAL, HISTOPATHOLOGICAL, AND MOLECULAR BIOLOGICAL CHARACTERISTICS
Critical Reviews in Oral Biology & Medicine, January 1, 2003; 14(1): 47 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
V. A. Papadimitrakopoulou, D. D. Liu, L. Mao, D. M. Shin, A. El-Naggar, H. Ibarguen, J. J. Lee, W. K. Hong, and W. N. Hittelman
Biologic Correlates of a Biochemoprevention Trial in Advanced Upper Aerodigestive Tract Premalignant Lesions
Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1605 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Lippman and W. K. Hong
Cancer Prevention Science and Practice
Cancer Res., September 15, 2002; 62(18): 5119 - 5125.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
F. McGregor, A. Muntoni, J. Fleming, J. Brown, D. H. Felix, D. G. MacDonald, E. K. Parkinson, and P. R. Harrison
Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality: Potential for Its Reversal by 5-Azacytidine
Cancer Res., August 15, 2002; 62(16): 4757 - 4766.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I Cruz, S S Napier, I van der Waal, P J F Snijders, J M M Walboomers, P J Lamey, C G Cowan, T A Gregg, P Maxwell, and C J L M Meijer
Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland
J. Clin. Pathol., February 1, 2002; 55(2): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Lippman and W. Ki Hong
Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002.
Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al.
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia
Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Sudbo, W. Kildal, A. C. Johannessen, H. S. Koppang, A. Sudbo, H. E. Danielsen, B. Risberg, and A. Reith
Gross Genomic Aberrations in Precancers: Clinical Implications of a Long-Term Follow-Up Study in Oral Erythroplakias
J. Clin. Oncol., January 15, 2002; 20(2): 456 - 462.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Lippman and M. R. Spitz
Lung Cancer Chemoprevention: An Integrated Approach
J. Clin. Oncol., September 15, 2001; 19(90001): 74s - 82.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. M. Lippman and W. K. Hong
Molecular Markers of the Risk of Oral Cancer
N. Engl. J. Med., April 26, 2001; 344(17): 1323 - 1326.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. M. Lippman, J. J. Lee, D. D. Karp, E. E. Vokes, S. E. Benner, G. E. Goodman, F. R. Khuri, R. Marks, R. J. Winn, W. Fry, et al.
Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer
J Natl Cancer Inst, April 18, 2001; 93(8): 605 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Kim, D. M. Shin, A. El-Naggar, J. S. Lee, C. Corrales, S. M. Lippman, W. K. Hong, and W. N. Hittelman
Chromosome Polysomy and Histological Characteristics in Oral Premalignant Lesions
Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 319 - 325.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. M. Lippman and L. M. Matrisian
Protease Inhibitors in Oral Carcinogenesis and Chemoprevention
Clin. Cancer Res., December 1, 2000; 6(12): 4599 - 4603.
[Full Text]

Home page
 JCOHome page
W. K. Hong, M. R. Spitz, and S. M. Lippman
Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets
J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. Trock
Out of the Mouths of Babes: Oral Premalignant Lesions and Use of Alternative Tobacco Products
Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 637 - 638.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.